Table 1 Definitions of terms in included studies
Study | Study design | Setting | Drug dose (mg/day) | Median follow up (months) | eGFR (ml/min/1.73Â m2) | Range of Hgb A1c | Primary outcome | Definition of renal outcomes |
|---|---|---|---|---|---|---|---|---|
SGLT2i vs placebo | ||||||||
 CANVAS Program | RCT | Multinational | Canagliflozin 300/100 | 29.0 | 30–59 | 7.0–10.5 | MACE | ≥ 40% eGFR decline, ESRD, renal death |
 CREDENCE | RCT | Multinational | Canagliflozin 100 | 31.4 | 30–59 | 6.5–12.0 | Renal outcomes | Doubing creatinine, ESRD, renal or CV death |
 DECLARE-TIMI 58 | RCT | Multinational | Dapagliflozin 10 | 50.4 | <60 | 6.5–12.0 | MACE | ≥ 40% eGFR decline, ESRD, renal or CVdeath |
 EMPA-REG OUTCOME | RCT | Multinational | Empagliflozin 10/25 | 37.2 | 30–59 | 7.0–9.0 | MACE | Doubling creatinine, ESRD, renal death |
 SCORED | RCT | Multinational | Sotagliflozin 400 | 16.0 | 25–60 | > 7.0 | MACE | ≥ 50% eGFR decline, ESRD |
 VERTIS-CV | RCT | Multinational | Ertugliflozin 5/15 | 36.0 | 30–59 | 7.0–10.5 | MACE | Doubing creatinine, ESRD, renal death |
GLP-1 RA vs placebo | ||||||||
 ELIXA | RCT | Multinational | Lixisenatide 20 mcg | 25.2 | 30–59 | 5.5–11.0 | MACE (including unstable angina) | N/A |
 EXSCEL | RCT | Multinational | Exenatide 2 (weekly) | 38.4 | 30–59 | 6.5–10 | MACE | ≥ 40% EGFR decline, ESRD, renal death |
 HARMONY Outcomes | RCT | Multinational | Albiglutide 30/50 | 19.2 | 30–59 | > 7.0 | MACE | N/A |
 LEADER | RCT | Multinational | Liraglutide 1.8 | 45.6 | 30–59 | > 7.0 | MACE | Doubling of serum creatinine, ESRD |
 PIONEER-6 | RCT | Multinational | Semaglutide 14 (oral) | 15.9 | 30–59 | N/A | MACE | N/A |
 REWIND | RCT | Multinational | Dulaglutide 1.5 (weekly) | 64.8 | 15–59 | < 9.5 | MACE | ≥ 30% eGFR decline, ESRD, renal death |
 SUSTAIN-6 | RCT | Multinational | Semaglutide 0.5/1 (weekly) | 25.2 | <60 | > 7.0 | MACE | N/A |